Why Co-Diagnostics, Inc.’s (CODX) Stock Is Down 53.25%
As of Tuesday, October 28, Co-Diagnostics, Inc.’s CODX share price has dipped by 53.25%, which has investors questioning if this is right time to buy.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. Co-Diagnostics, Inc. was incorporated in 2013 and is based in Salt Lake City, Utah.
Commentary & Analysis
7 Undervalued Health Care Equipment & Supplies Stocks for Friday, October 18
Discover the top 7 undervalued Health Care Equipment & Supplies stocks for Friday, October 18 based on AAII’s Stock Grades.Omar Beirat
3 Undervalued Advanced Medical Equipment & Technology Stocks for Thursday, March 21
Discover the top 3 undervalued Advanced Medical Equipment & Technology stocks for Thursday, March 21 based on AAII’s Stock Grades.Jenna Brashear
3 Undervalued Advanced Medical Equipment & Technology Stocks for Tuesday, February 13
Discover the top 3 undervalued Advanced Medical Equipment & Technology stocks for Tuesday, February 13 based on AAII’s Stock Grades.Jenna Brashear
3 Undervalued Advanced Medical Equipment & Technology Stocks for Monday, December 25
Discover the top 3 undervalued Advanced Medical Equipment & Technology stocks for Monday, December 25 based on AAII’s Stock Grades.Eunice Kim
Financial Summary
| Share Statistics | CODX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $7.2 | $407.7 | 5% |
|
| Shares Out (Mil) | 4.3 | 41.3 | 12% |
|
| Institutional Ownership | 75.4% | 81.4% | 46% |
|
| Float (Mil) | 5.2 | 34.9 | 12% |
|
| Beta | 2.88 | 0.88 | 98% |
|
| Avg Daily Volume (000s) | 481 | 412 | 57% |
|
| Price Change (52-week) |
(86.8%) | 64.8% | 5% |
|
| Growth | CODX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (61.9%) | 11.8% | 0% |
|
| Net Income (5yr) | (25.4%) | (6.0%) | 16% |
|
| EPS (5yr) | (22.6%) | 10.4% | 12 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (32.3%) | (16.2%) | 17% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | na | 1 | |
| Current EPS | ($1.250) | ($3.100) | ($0.830) | |
| Month Ago EPS | ($3.300) | ($13.500) | ($12.000) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($2.850) | ($12.150) | ($12.000) | |
| Year/Year Chg | (14.4%) | (91.2%) | (99.2%) | |
| Financials | CODX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $119 | 1% |
|
| Net Income (TTM) (Mil) | ($47) | ($9) | 17% |
|
| EPS (TTM) | ($19.358) | ($0.400) | 2% |
|
| Operating Cash Flow (TTM) (Mil) | ($27) | ($3) | 13% |
|
| Net Cash Flow (TTM) (Mil) | ($8) | $1 | 32% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $21 | 17% |
|
| Enterprise Value (Q1) (Mil) | $5 | $427 | 5% |
|
| Valuation | CODX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.44 | 3.06 | 7% |
|
| P/E | na | 27.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.7 | na |
|
| Ratios | CODX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 43.5% | 58.9% | 54% |
|
| Net Margin | na | (6.9%) | na |
|
| ROA | (149.3%) | (12.7%) | 3% |
|
| ROE | (174.8%) | (13.1%) | 5% |
|
| Liabilities to Assets | 23.4% | 46.0% | 16% |
|
| F-Score | 2 | 4 | 7% |
|
Co-Diagnostics, Inc. did not pass any screens on 8/20/2026.
